Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5961408 | 1.00 | PYGL (1.00) | PYGLEGFR | |
| SCHEMBL25346025 | 0.92 | PYGL (0.84) | PYGLEGFR | |
| SCHEMBL13095874 | 0.92 | PYGL (0.84) | PYGLEGFR | |
| SCHEMBL12314033 | 0.92 | PYGL (0.84) | PYGLEGFR | |
| SCHEMBL7237994 | 0.92 | PYGL (0.84) | PYGLEGFR | |
| SCHEMBL7243055 | 0.90 | PYGL (0.81) | PYGLEGFR | |
| SCHEMBL6634027 | 0.90 | PYGL (1.00) | PYGLEGFR | |
| SCHEMBL7738842 | 0.90 | PYGL (1.00) | PYGLEGFR | |
| SCHEMBL2607008 | 0.86 | PYGL (0.75) | PYGL | |
| SCHEMBL2106925 | 0.86 | PYGL (0.75) | PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| US-20240415791-A1 | Therapeutic methods and compositions for treating cancer using devimistat and a fatty acid oxidation inhibitor, a tyrosine kinase inhibitor, a glutaminase inhibitor, and/or a glycolysis inhibitor | CORNERSTONE PHARMACEUTICALS INC (US) | 2024-12-19 | — | — | US | claimed |
| US-20230255974-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2023-08-17 | — | — | US | claimed |
| US-20200215031-A1 | METHOD OF TREATING CANCER WITH AN ELEVATED GLYCOGEN CONTENT | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2020-07-09 | — | — | US | claimed |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2003-01-02 | — | — | US | claimed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | claimed |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | disclosed |
| CN-119700983-A | Application of UBR5 in preparation of medicines for treating pigment dermatosis | 中南大学湘雅医院 | 2025-03-28 | — | — | CN | disclosed |
| US-20240415791-A1 | Therapeutic methods and compositions for treating cancer using devimistat and a fatty acid oxidation inhibitor, a tyrosine kinase inhibitor, a glutaminase inhibitor, and/or a glycolysis inhibitor | CORNERSTONE PHARMACEUTICALS INC (US) | 2024-12-19 | — | — | US | disclosed |
| US-20230255974-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2023-08-17 | — | — | US | disclosed |
| US-11712432-B2 | Method of treating cancer with an elevated glycogen content | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2023070101-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING CANCER USING DEVIMISTAT AND A FATTY ACID OXIDATION INHIBITOR, A TYROSINE KINASE INHIBITOR, A GLUTAMINASE INHIBITOR, AND/OR A GLYCOLYSIS INHIBITOR | CORNERSTONE PHARMACEUTICALS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20200215031-A1 | METHOD OF TREATING CANCER WITH AN ELEVATED GLYCOGEN CONTENT | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2020-07-09 | — | — | US | disclosed |
| WO-2006043036-A2 | TREATMENT OF DIABETES | THE UNIVERSITY OF NEWCASTLE (GB) | 2006-04-27 | — | — | WO | disclosed |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2003-01-02 | — | — | US | disclosed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415791-A1 | Therapeutic methods and compositions for treating cancer using devimistat and a fatty acid oxidation inhibitor, a tyrosine kinase inhibitor, a glutaminase inhibitor, and/or a glycolysis inhibitor | PDK4, PDK2, PDK1 | PYGL 779/4885EGFR 238/4885 |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | THRA, THRB, TRHR | PYGL 1869/4885EGFR 1068/4885 |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | PYGL, PYGM, GYS2 | PYGL 1/4885EGFR 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.